Buscar
Novo Nordisk A/S
NVOAñadir a la lista de seguimiento
46.600USD
-0.910-1.92%
Cierre 09-04 16:00（ET）
156.20BCap. mercado
10.91P/E TTM
Más Datos de Novo Nordisk A/S Compañía
Novo Nordisk A/S is a global healthcare company engaged in diabetes care. The Company is also engaged in the discovery, development, manufacturing and marketing of pharmaceutical products. The Company operates through two business segments: diabetes and obesity care, and biopharmaceuticals. The Company's diabetes and obesity care segment covers insulin, GLP-1, other protein-related products, such as glucagon, protein-related delivery systems and needles, and oral anti-diabetic drugs. The Company's biopharmaceuticals segment covers the therapy areas of hemophilia care, growth hormone therapy and hormone replacement therapy. The Company also offers Saxenda product to treat obesity. It offers a range of products, including NovoLog/NovoRapid; NovoLog Mix/NovoMix; Prandin/NovoNorm; NovoSeven; Norditropin, and Vagifem. As of December 31, 2016, it marketed its products in over 180 countries. Its regional structure consists of two commercial units: North America and International Operations.
Perfil de Novo Nordisk A/S
Símbolo de cotizaciónNVO
Nombre de la empresaNovo Nordisk A/S
Fecha de salida a bolsaMay 17, 1974
Director ejecutivoDoustdar (Maziar Mike)
Número de empleados76302
Tipo de seguridadDepository Receipt
Fin del año fiscalMay 17
DirecciónNovo Alle 1
CiudadBAGSVAERD
Bolsa de valoresNASDAQ OMX NASDAQ Basic NYSE
PaísDenmark
Código postal2880
Teléfono4544448888
Sitio Webhttps://www.novonordisk.com/
Símbolo de cotizaciónNVO
Fecha de salida a bolsaMay 17, 1974
Director ejecutivoDoustdar (Maziar Mike)
Ejecutivos de Novo Nordisk A/S
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Desiree Jantzen Asgreen
Ms. Desiree Jantzen Asgreen
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Helena Saxon
Ms. Helena Saxon
Independent Director
Independent Director
--
--
Dr. Jan van de Winkel, Ph.D.
Dr. Jan van de Winkel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Mr. Kasim Kutay
Mr. Kasim Kutay
Director
Director
--
--
Ms. Mette Boejer Jensen
Ms. Mette Boejer Jensen
Director, Employee Representative
Director, Employee Representative
--
--
Mr. Karsten Munk Knudsen
Mr. Karsten Munk Knudsen
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
--
--
Mr. Ludovic Helfgott
Mr. Ludovic Helfgott
Executive Vice President - Product and Portfolio Strategy
Executive Vice President - Product and Portfolio Strategy
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Ms. Desiree Jantzen Asgreen
Ms. Desiree Jantzen Asgreen
Director, Employee Representative
Director, Employee Representative
--
--
Ms. Helena Saxon
Ms. Helena Saxon
Independent Director
Independent Director
--
--
Dr. Jan van de Winkel, Ph.D.
Dr. Jan van de Winkel, Ph.D.
Independent Director
Independent Director
--
--
Ms. Ramona A. Sequeira
Ms. Ramona A. Sequeira
Independent Director
Independent Director
--
--
Mr. Lars Rebien Soerensen
Mr. Lars Rebien Soerensen
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Maziar Mike Doustdar
Mr. Maziar Mike Doustdar
President, Chief Executive Officer
President, Chief Executive Officer
--
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Novo Nordisk A/S?
Los cinco principales accionistas de Novo Nordisk A/S son: Ms. Desiree Jantzen Asgreen
¿Cuántas instituciones poseen acciones de Novo Nordisk A/S (NVO)?
A fecha de 2026Q1, 2975 instituciones poseen acciones de Novo Nordisk A/S, con un valor de mercado combinado de aproximadamente 332.82M, lo que representa el 9.89% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -2714627.00.
¿Cuál es la mayor fuente de ganancias de Novo Nordisk A/S?
El 2026Q1, el segmento empresarial Total GLP-1 generó la ganancia más alta para Novo Nordisk A/S, ascendiendo a 5.72B y representando el 46.87% de la ganancia total.